Literature DB >> 25416468

Relationship between iron accumulation and white matter injury in multiple sclerosis: a case-control study.

Eytan Raz1, Brittany Branson, Jens H Jensen, Maxim Bester, James S Babb, Joseph Herbert, Robert I Grossman, Matilde Inglese.   

Abstract

Despite the increasing development and applications of iron imaging, the pathophysiology of iron accumulation in multiple sclerosis (MS), and its role in disease progression and development of clinical disability, is poorly understood. The aims of our study were to determine the presence and extent of iron in T2 visible lesions and gray and white matter using magnetic field correlation (MFC) MRI and correlate with microscopic white matter (WM) injury as measured by diffusion tensor imaging (DTI). This is a case-control study including a series of 31 patients with clinically definite MS. The mean age was 39 years [standard deviation (SD) = 9.55], they were 11 males and 20 females, with a disease duration average of 3 years (range 0-13) and a median EDSS of 2 (0-4.5). Seventeen healthy volunteers (6 males and 11 females) with a mean age of 36 years (SD = 11.4) were recruited. All subjects underwent MR imaging on a 3T scanner using T2-weighted sequence, 3D T1 MPRAGE, MFC, single-shot DTI and post-contrast T1. T2-lesion volumes, brain volumetry, DTI parameters and iron quantification were calculated and multiple correlations were exploited. Increased MFC was found in the putamen (p = 0.061), the thalamus (p = 0.123), the centrum semiovale (p = 0.053), globus pallidus (p = 0.008) and gray matter (GM) (p = 0.004) of MS patients compared to controls. The mean lesional MFC was 121 s(-2) (SD = 67), significantly lower compared to the GM MFC (<0.0001). The GM mean diffusivity (MD) was inversely correlated with the MFC in the centrum semiovale (p < 0.001), and in the splenium of the corpus callosum (p < 0.001). Patients with MS have increased iron in the globus pallidus, putamen and centrum with a trend toward increased iron in all the brain structures. Quantitative iron evaluation of WM and GM may improve the understanding of MS pathophysiology, and might serve as a surrogate marker of disease progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25416468      PMCID: PMC4452503          DOI: 10.1007/s00415-014-7569-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion.

Authors:  Michael H Barnett; John W Prineas
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

2.  Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls.

Authors:  C A Habib; M Liu; N Bawany; J Garbern; I Krumbein; H-J Mentzel; J Reichenbach; C Magnano; R Zivadinov; E M Haacke
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-24       Impact factor: 3.825

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

4.  Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients.

Authors:  R Bakshi; J Dmochowski; Z A Shaikh; L Jacobs
Journal:  J Neurol Sci       Date:  2001-03-15       Impact factor: 3.181

5.  Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy.

Authors:  J Hagemeier; B Weinstock-Guttman; N Bergsland; M Heininen-Brown; E Carl; C Kennedy; C Magnano; D Hojnacki; M G Dwyer; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-29       Impact factor: 3.825

Review 6.  Oligodendrocytes and myelination: the role of iron.

Authors:  Bozho Todorich; Juana M Pasquini; Corina I Garcia; Pablo M Paez; James R Connor
Journal:  Glia       Date:  2009-04-01       Impact factor: 7.452

7.  Magnetic field correlation as a measure of iron-generated magnetic field inhomogeneities in the brain.

Authors:  Jens H Jensen; Kamila Szulc; Caixia Hu; Anita Ramani; Hanzhang Lu; Liang Xuan; Maria F Falangola; Ramesh Chandra; Edmond A Knopp; John Schenck; Earl A Zimmerman; Joseph A Helpern
Journal:  Magn Reson Med       Date:  2009-02       Impact factor: 4.668

8.  Evaluating and reducing the impact of white matter lesions on brain volume measurements.

Authors:  Marco Battaglini; Mark Jenkinson; Nicola De Stefano
Journal:  Hum Brain Mapp       Date:  2011-08-31       Impact factor: 5.038

9.  Iron and neurodegeneration in multiple sclerosis.

Authors:  Michael Khalil; Charlotte Teunissen; Christian Langkammer
Journal:  Mult Scler Int       Date:  2011-02-10

10.  Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.

Authors:  Veela Mehta; Wei Pei; Grant Yang; Suyang Li; Eashwar Swamy; Aaron Boster; Petra Schmalbrock; David Pitt
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more
  10 in total

1.  Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality.

Authors:  Ferdinand Schweser; Ana Luiza Raffaini Duarte Martins; Jesper Hagemeier; Fuchun Lin; Jannis Hanspach; Bianca Weinstock-Guttman; Simon Hametner; Niels Bergsland; Michael G Dwyer; Robert Zivadinov
Journal:  Neuroimage       Date:  2017-10-31       Impact factor: 6.556

2.  Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Authors:  A Burgetova; P Dusek; M Vaneckova; D Horakova; C Langkammer; J Krasensky; L Sobisek; P Matras; M Masek; Z Seidl
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

Review 3.  Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Authors:  Heather Y F Yong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2021-11-03       Impact factor: 42.937

4.  Lesion Expansion in Experimental Demyelination Animal Models and Multiple Sclerosis Lesions.

Authors:  René Große-Veldmann; Birte Becker; Sandra Amor; Paul van der Valk; Cordian Beyer; Markus Kipp
Journal:  Mol Neurobiol       Date:  2015-09-12       Impact factor: 5.590

5.  Can T2 blackout effect be a marker of iron accumulation in brains of multiple sclerosis patients?

Authors:  Mehmet Fatih Erbay; Özden Kamışlı; Nur Betül Karatoprak
Journal:  Br J Radiol       Date:  2020-07-08       Impact factor: 3.039

Review 6.  Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping.

Authors:  Carsten Stüber; David Pitt; Yi Wang
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

7.  Increased Brain Iron Detection by Voxel-Based Quantitative Susceptibility Mapping in Type 2 Diabetes Mellitus Patients With an Executive Function Decline.

Authors:  Jing Li; Qihao Zhang; Nan Zhang; Lingfei Guo
Journal:  Front Neurosci       Date:  2021-01-15       Impact factor: 4.677

8.  Iron Deposition Characteristics of Deep Gray Matter in Elderly Individuals in the Community Revealed by Quantitative Susceptibility Mapping and Multiple Factor Analysis.

Authors:  Jing Li; Qihao Zhang; Yena Che; Nan Zhang; Lingfei Guo
Journal:  Front Aging Neurosci       Date:  2021-04-14       Impact factor: 5.750

9.  A Preliminary Study of Alterations in Iron Disposal and Neural Activity in Ischemic Stroke.

Authors:  Abolfazl Mahmoudi Aqeel-Abadi; Hamid-Reza Fateh; Saeed Masoudnia; Niloufar Shirzad; Milad Seyfi; Tayyebeh Ebrahimi; Mohammad-Reza Nazem-Zadeh
Journal:  Biomed Res Int       Date:  2022-08-06       Impact factor: 3.246

10.  Histological validation of fast macromolecular proton fraction mapping as a quantitative myelin imaging method in the cuprizone demyelination model.

Authors:  Marina Yu Khodanovich; Irina V Sorokina; Valentina Yu Glazacheva; Andrey E Akulov; Nikolay M Nemirovich-Danchenko; Alexander V Romashchenko; Tatyana G Tolstikova; Lilia R Mustafina; Vasily L Yarnykh
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.